Indivior Pharmaceuticals to Present New Research Posters at American Society of Addiction Medicine Annual Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy INDV?
Indivior Pharmaceuticals will present one new scientific poster and collaborated with VA Tech on a second poster which will be presented at the American Society of Addiction Medicine Annual Conference, held April 23-26, 2026, in San Diego, California. The data add to the growing body of evidence evaluating extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE, in supporting meaningful outcomes for people living with OUD, including overdose-related outcomes and broader indicators associated with recovery. Impact of OAT in individuals with OUD who experienced an overdose in Ontario, Canada: This retrospective nested case-control study used Ontario administrative health data of more than 45,000 patients with OUD to evaluate associations between MOUD treatments, including SUBLOCADE, transmucosal buprenorphine, methadone, and sustained-release oral morphine and the risk of opioid-related fatal and non-fatal overdose. Most overdose events occurred off treatment: Patients with higher MOUD coverage experienced less non-fatal and fatal overdose compared to those with lower MOUD coverage. Buprenorphine-based MOUD significantly reduced overdose risk: Of all MOUD, SUBLOCADE accounted for the smallest proportion of non-fatal and fatal OD events compared to no treatment. Both SUBLOCADE and TM-BUP had the lowest odds of all MOUD odds of non-fatal and fatal overdose versus no MOUD. Study limitations include potential misclassification in administrative data, incomplete or inaccurate capture of opioid-related OD events and OAT use, and absence of a direct measure of OAT adherence. Associations between remission from opioid use disorder and treatment-relevant outcomes: Provisional findings from the Remission from OUD as a Treatment Endpoint followed 443 participants within 0-3 months of starting treatment with SUBLOCADE for up to 12 months to understand how OUD remission relates to treatment-relevant and recovery-related outcomes. Remission as an indicator of improved outcomes: Individuals entering the study in remission for 3-months indicated lower craving, lower withdrawal, lower pain, better quality of life, and lower rates of unemployment than those not in remission. Complete abstinence may neither be sufficient nor necessary: Opioid misuse and OUD remission are not always consistent; an individual may abstain from opioid misuse while not yet meeting criteria for 3-month remission, underscoring the importance of remission as a clinically meaningful treatment endpoint. One study limitation is that participants entered at varying BUP-XR treatment durations, so study entry does not align with treatment initiation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INDV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INDV
Wall Street analysts forecast INDV stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 34.430
Low
36.00
Averages
43.75
High
50.00
Current: 34.430
Low
36.00
Averages
43.75
High
50.00
About INDV
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Indivior Collaborates with Virginia Tech on Opioid Use Disorder Research
- Research Presentation: Indivior showcased collaborative research with Virginia Tech at the American Society of Addiction Medicine annual conference, highlighting the efficacy of extended-release buprenorphine (SUBLOCADE®) in improving quality of life and reducing overdose risks for opioid use disorder patients, thereby reinforcing its leadership in the opioid treatment sector.
- Reduced Overdose Risk: The study indicates that patients treated with buprenorphine had the lowest proportions of non-fatal and fatal overdose events, particularly when treatment coverage exceeded 80%, providing crucial evidence for clinical practice regarding effective treatment strategies.
- Importance of Remission Indicators: In a study involving 443 participants, those entering remission showed better outcomes in terms of reduced cravings, withdrawal symptoms, and improved quality of life, emphasizing the significance of remission as a treatment endpoint beyond mere abstinence criteria.
- Long-term Commitment: Indivior's Chief Scientific Officer stated that for 25 years, the company has been dedicated to advancing science that improves care for opioid use disorder patients, demonstrating ongoing efforts to promote effective treatment and expand access to quality care.
See More
Indivior Releases Survey Results on Medication Use in Correctional Facilities
- Survey Overview: Indivior's survey reveals that 88% of jail staff and 87% of prison personnel believe that long-acting injectable buprenorphine can effectively reduce medication for opioid use disorder (MOUD) diversion, indicating its potential in correctional settings.
- Implementation Barriers Identified: The survey also highlights structural barriers to effective MOUD program implementation, including inadequate medical and custody staffing, limited coordination between health services and custody, and operational challenges related to medication administration and monitoring, which hinder effective treatment delivery.
- Policy Recommendations: The findings underscore the need for policies and funding strategies to strengthen staffing capacity, enhance care coordination, and ensure sustainable MOUD delivery during incarceration and throughout reentry into the community, thereby supporting long-term recovery.
- Industry Impact: Indivior executives emphasize that simplified treatment models can improve patient access while enhancing institutional operational efficiency, reinforcing the significance of long-acting injectable buprenorphine as a viable implementation strategy.
See More
SUBLOCADE® Reduces Staffing Costs in Prisons
- Staff Time Savings: The use of SUBLOCADE® in correctional facilities results in a reduction of 318 staff hours per month compared to methadone, significantly lowering labor costs and enhancing operational efficiency to address staffing shortages.
- Significant Cost Benefits: Monthly cost savings range from $23 to $22,148, with the largest savings stemming from the elimination of daily observed dosing and patient escorts, indicating SUBLOCADE®'s economic advantages.
- Improved Treatment Efficiency: Compared to other medications, SUBLOCADE®'s monthly injections reduce reliance on staff, enabling prisons to provide evidence-based care more efficiently and meet the growing demand for opioid use disorder treatment.
- Support for Policy Goals: Indivior's research underscores the potential of more efficient medication delivery models to advance public policy goals and improve health outcomes, highlighting SUBLOCADE®'s strategic significance in public health.
See More
Significant Gaps in MOUD Access Across U.S. Prisons
- Access to Treatment Lacking: Indivior's study reveals that only 58% of jails and detention centers offer at least one FDA-approved medication for opioid use disorder (MOUD), highlighting significant deficiencies in the U.S. correctional system's treatment capabilities, particularly in the South and Midwest.
- Regional Disparities: Jails are more than twice as likely to provide MOUD compared to prisons, with facilities in the West having over three times the odds of offering MOUD than those in the Midwest, exacerbating treatment access inequalities across regions.
- Urgent Need for Reentry Support: The survey indicates that approximately 17% of inmates meet the criteria for opioid use disorder, yet the overdose mortality risk in the first two weeks post-release is 40 times higher than the national average, underscoring the critical need for MOUD during incarceration.
- Necessity for Improved Transition Services: Respondents emphasized the importance of transitional housing, job training, and community support networks for sustaining recovery, indicating that establishing effective continuity of care between incarceration and community services is vital for addressing opioid use disorder.
See More
Indivior Announces $450M Convertible Notes Offering
- Increased Offering Size: Indivior Pharmaceuticals has raised the size of its convertible senior notes offering from an initial $400 million to $450 million, indicating strong market interest in its financing needs and enhancing the company's financial flexibility.
- Interest Rate and Maturity: The notes carry an annual interest rate of 0.625% and will mature on March 15, 2031, with interest payments made semi-annually starting September 15, 2026, providing the company with a low-cost financing avenue to support future growth.
- Clear Use of Proceeds: Indivior anticipates net proceeds of approximately $437.7 million from this offering, with around $239 million allocated to pay down part of its term loan, $75 million for repurchasing about 2.4 million shares of common stock, and the remainder for general corporate purposes, reflecting the company's focus on optimizing its capital structure.
- Attractive Conversion Terms: The initial conversion rate is set at 24.0033 shares per $1,000 principal, translating to a conversion price of about $41.66 per share, representing a 35% premium over the common stock price reported on March 12, 2026, providing investors with potential capital appreciation opportunities.
See More
Indivior Prices Upsized $450 Million Convertible Notes Offering
- Upsized Offering: Indivior Pharmaceuticals Inc. has increased its convertible notes offering from $400 million to $450 million, indicating strong market demand, with the transaction expected to close on March 17, enhancing the company's liquidity.
- Interest and Conversion Terms: The 0.625% convertible notes will mature in 2031, with an initial conversion rate of 24.0033 shares per $1,000 principal amount, translating to a conversion price of approximately $41.66 per share, representing a 35% premium over the last reported share price on March 12, providing investors with potential capital appreciation.
- Clear Use of Proceeds: Indivior plans to allocate about $239 million of the proceeds to repay borrowings and terminate its credit facility agreements, while approximately $75 million will be used to repurchase around 2.4 million common shares, demonstrating the company's focus on optimizing its capital structure.
- Stock Price Volatility: Indivior's stock closed down 6% at $30.86 on March 13, and further declined to $30.64 in after-hours trading, reflecting market caution regarding the upsized offering, which may impact investor confidence.
See More
Indivior Collaborates with Virginia Tech on Opioid Use Disorder Research
- Research Presentation: Indivior showcased collaborative research with Virginia Tech at the American Society of Addiction Medicine annual conference, highlighting the efficacy of extended-release buprenorphine (SUBLOCADE®) in improving quality of life and reducing overdose risks for opioid use disorder patients, thereby reinforcing its leadership in the opioid treatment sector.
- Reduced Overdose Risk: The study indicates that patients treated with buprenorphine had the lowest proportions of non-fatal and fatal overdose events, particularly when treatment coverage exceeded 80%, providing crucial evidence for clinical practice regarding effective treatment strategies.
- Importance of Remission Indicators: In a study involving 443 participants, those entering remission showed better outcomes in terms of reduced cravings, withdrawal symptoms, and improved quality of life, emphasizing the significance of remission as a treatment endpoint beyond mere abstinence criteria.
- Long-term Commitment: Indivior's Chief Scientific Officer stated that for 25 years, the company has been dedicated to advancing science that improves care for opioid use disorder patients, demonstrating ongoing efforts to promote effective treatment and expand access to quality care.
See More
Indivior Releases Survey Results on Medication Use in Correctional Facilities
- Survey Overview: Indivior's survey reveals that 88% of jail staff and 87% of prison personnel believe that long-acting injectable buprenorphine can effectively reduce medication for opioid use disorder (MOUD) diversion, indicating its potential in correctional settings.
- Implementation Barriers Identified: The survey also highlights structural barriers to effective MOUD program implementation, including inadequate medical and custody staffing, limited coordination between health services and custody, and operational challenges related to medication administration and monitoring, which hinder effective treatment delivery.
- Policy Recommendations: The findings underscore the need for policies and funding strategies to strengthen staffing capacity, enhance care coordination, and ensure sustainable MOUD delivery during incarceration and throughout reentry into the community, thereby supporting long-term recovery.
- Industry Impact: Indivior executives emphasize that simplified treatment models can improve patient access while enhancing institutional operational efficiency, reinforcing the significance of long-acting injectable buprenorphine as a viable implementation strategy.
See More
SUBLOCADE® Reduces Staffing Costs in Prisons
- Staff Time Savings: The use of SUBLOCADE® in correctional facilities results in a reduction of 318 staff hours per month compared to methadone, significantly lowering labor costs and enhancing operational efficiency to address staffing shortages.
- Significant Cost Benefits: Monthly cost savings range from $23 to $22,148, with the largest savings stemming from the elimination of daily observed dosing and patient escorts, indicating SUBLOCADE®'s economic advantages.
- Improved Treatment Efficiency: Compared to other medications, SUBLOCADE®'s monthly injections reduce reliance on staff, enabling prisons to provide evidence-based care more efficiently and meet the growing demand for opioid use disorder treatment.
- Support for Policy Goals: Indivior's research underscores the potential of more efficient medication delivery models to advance public policy goals and improve health outcomes, highlighting SUBLOCADE®'s strategic significance in public health.
See More
Significant Gaps in MOUD Access Across U.S. Prisons
- Access to Treatment Lacking: Indivior's study reveals that only 58% of jails and detention centers offer at least one FDA-approved medication for opioid use disorder (MOUD), highlighting significant deficiencies in the U.S. correctional system's treatment capabilities, particularly in the South and Midwest.
- Regional Disparities: Jails are more than twice as likely to provide MOUD compared to prisons, with facilities in the West having over three times the odds of offering MOUD than those in the Midwest, exacerbating treatment access inequalities across regions.
- Urgent Need for Reentry Support: The survey indicates that approximately 17% of inmates meet the criteria for opioid use disorder, yet the overdose mortality risk in the first two weeks post-release is 40 times higher than the national average, underscoring the critical need for MOUD during incarceration.
- Necessity for Improved Transition Services: Respondents emphasized the importance of transitional housing, job training, and community support networks for sustaining recovery, indicating that establishing effective continuity of care between incarceration and community services is vital for addressing opioid use disorder.
See More
Indivior Announces $450M Convertible Notes Offering
- Increased Offering Size: Indivior Pharmaceuticals has raised the size of its convertible senior notes offering from an initial $400 million to $450 million, indicating strong market interest in its financing needs and enhancing the company's financial flexibility.
- Interest Rate and Maturity: The notes carry an annual interest rate of 0.625% and will mature on March 15, 2031, with interest payments made semi-annually starting September 15, 2026, providing the company with a low-cost financing avenue to support future growth.
- Clear Use of Proceeds: Indivior anticipates net proceeds of approximately $437.7 million from this offering, with around $239 million allocated to pay down part of its term loan, $75 million for repurchasing about 2.4 million shares of common stock, and the remainder for general corporate purposes, reflecting the company's focus on optimizing its capital structure.
- Attractive Conversion Terms: The initial conversion rate is set at 24.0033 shares per $1,000 principal, translating to a conversion price of about $41.66 per share, representing a 35% premium over the common stock price reported on March 12, 2026, providing investors with potential capital appreciation opportunities.
See More
Indivior Prices Upsized $450 Million Convertible Notes Offering
- Upsized Offering: Indivior Pharmaceuticals Inc. has increased its convertible notes offering from $400 million to $450 million, indicating strong market demand, with the transaction expected to close on March 17, enhancing the company's liquidity.
- Interest and Conversion Terms: The 0.625% convertible notes will mature in 2031, with an initial conversion rate of 24.0033 shares per $1,000 principal amount, translating to a conversion price of approximately $41.66 per share, representing a 35% premium over the last reported share price on March 12, providing investors with potential capital appreciation.
- Clear Use of Proceeds: Indivior plans to allocate about $239 million of the proceeds to repay borrowings and terminate its credit facility agreements, while approximately $75 million will be used to repurchase around 2.4 million common shares, demonstrating the company's focus on optimizing its capital structure.
- Stock Price Volatility: Indivior's stock closed down 6% at $30.86 on March 13, and further declined to $30.64 in after-hours trading, reflecting market caution regarding the upsized offering, which may impact investor confidence.
See More
